new report multipl driver beyond copaxon nuvar
upgrad outperform
upgrad drl outperform under-perform tp
concern high market
expect copaxon nuvar stock
extrem ignor aforement drug strong
us pipelin multipl option valuestherefor upgrad
analysi show drl drug mn opportun
gkuvan/gciprodex/gremodulin reach bn sale
even without copaxone/nuvar concentr risk lower
top drug us sale vs
revlimid larg opportun drl see npv
mn even worst-cas scenario wherein assum eight
gener launch drl trial start
estim ebitda compound-annual-growth-rate doubl
tp lift factor revlimid npv ep
risk delay us approv lower india growth
china shift tender market upsid china
inject outlicens oral psoriasi molecul
figur us pipelin strong reach bn even without copaxon nuvar
base us pipelin bn sale even without
copaxone/nuvar drl multipl drug mn
opportun gkuvan gciprodex gremodulin help
base us sale continu grow concentr risk lower
top drug us sale vs
figur multipl mn drug us pipelin
estimate pot chg tp
number share mn
chg prev ep
revlimid npv mn even worst case drl case
ahead activ litig trial start celgen
settlement teva/alvogen allow entri post peak
share one-third/single-digit worst case assum
eight gener enter togeth drl npv still high
roce doubl three year drive re-rat drl
shown great execut control cost capital-expenditure
togeth high-margin launch us em scale-up
estim ebitda compound-annual-growth-rate doubl
valu india profit price-to-earnings em price-to-earnings copaxone/
nuvaring/suboxon price-to-earnings base profit
price-to-earnings risk delay us approv lower india growth
china shift tender market delay nuvar
figur sotp em account tp
upsid china inject file
outlicens oral psoriasi molecul paid
bn otezla lymphoma molecul bla
biosimilar rituximab
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
anubhav aggarw certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
price rate histori inc amgn oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
price rate histori dr reddi laboratori limit redi bo
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european rate base stock total return rel analyst coverag univers consist
compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun latin american asia stock exclud japan australia rate
base stock total return rel averag total return relev countri region benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti current share price
rel attract stock total return potenti within analyst coverag univers australian new zealand stock
expect total return calcul includ roll dividend yield outperform rate assign greater
charl martineau pm univers toronto equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk prior may
rang outperform under-perform rate overlap neutral threshold oper
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
